Evaluation of the PROSTia Test in Patients Undergoing Prostate Biopsy
Doctors are evaluating a new test called PROSTia, which uses artificial intelligence (AI) to help decide who really needs a prostate biopsy. Currently, the PSA test isn't always accurate, leading to many healthy men having biopsies they don't need. The PROSTia test combines PSA levels, information from a digital rectal examination (DRE), and other health data, using AI to give a risk score. The goal is to see if this new approach can help more accurately identify men who are at significant risk of prostate cancer, potentially avoiding painful and unnecessary biopsies for others, while still catching important cancers early.
At a glance
What is this study about?
Imagine you've had a check-up, and your doctor thinks there might be a small chance of prostate cancer, perhaps because of a blood test result (called a PSA test) or a physical exam. Often, the next step is a prostate biopsy, where small tissue samples are taken to be checked under a microscope. However, the PSA test isn't perfect, and many biopsies find no cancer, causing worry and discomfort for no reason.
This study is looking at a new way to decide if a biopsy is truly needed. It's called the PROSTia test, and it uses something called Artificial Intelligence (AI). Think of AI like a very smart computer program that can learn from lots of information. The PROSTia test takes your PSA levels, results from your digital rectal examination (DRE), and about 60 other pieces of health information, and then uses AI to analyse them all together. The goal is to get a much clearer picture of your actual risk of prostate cancer.
The main idea is that by using this clever AI approach, doctors can get a more accurate risk score. This score would help them decide if your risk is high enough to really need a biopsy, or if it's low enough that you could avoid one. Ultimately, they hope to reduce the number of unnecessary biopsies while still making sure that significant cancers are found early when treatment is most effective.
Key takeaways
- Tests an AI-powered tool (PROSTia) for prostate cancer screening.
- Aims to reduce unnecessary biopsies for suspected prostate cancer.
- Uses existing patient data (PSA, DRE, other health info) for analysis.
- The PROSTia test provides a risk score to guide biopsy decisions.
- Does not involve new treatments or procedures for participants.
- Contributes to developing better ways to detect prostate cancer.
Who may be eligible?
This study is looking for men aged 18 or older who are already being seen by the Urology Department at Nancy CHRU. You might be considered if your doctor believes a prostate biopsy is needed because of things like a high PSA blood test, how dense your PSA is, or if something unusual was spotted on an MRI scan.
To join, you must understand French well enough to complete a questionnaire, or have someone who can help you. You also need to be covered by a social security scheme. Importantly, you would need to be fully informed about the study and agree for your information to be used.
You cannot take part if you've already had a prostate biopsy before. Also, those under legal protection, guardianship, or who are in prison cannot participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you currently being seen by the Urology team at Nancy CHRU for suspected prostate cancer?
- Have you been told you might need a prostate biopsy?
- Have you NEVER had a prostate biopsy before?
- Can you understand French, or have someone help you with a questionnaire?
What does participation involve?
The study doesn't involve any extra visits or new medicines. If you are eligible and agree to take part, the PROSTia test will be performed using information that your doctors already collect as part of your standard care. This includes your PSA levels, the results of your digital rectal examination, and other health data. You would be asked to complete a questionnaire, possibly with help if needed. The PROSTia test itself is an analysis of this existing information, giving a score that helps predict your prostate cancer risk. There is no specific follow-up just for this study; your ongoing care for potential prostate cancer would continue as usual based on your doctor's assessment.
Potential risks and benefits
Locations (1)
- CHRU NancyVerified postcodeVandœuvre-lès-Nancy, France
Common questions
What is AI and how does it help in this study?
AI, or Artificial Intelligence, is a smart computer program that can learn from lots of medical information. Here, it helps analyse your test results to give doctors a more accurate idea of your prostate cancer risk.
Will taking part in this study change my prostate cancer treatment?
No, this study is about evaluating a new test. Your prostate cancer care will continue as usual, based on your doctor's recommendations and standard procedures.
What is a 'positive result' from the PROSTia test?
A positive result (a score of 1 or more) suggests you have a significant risk of developing prostate cancer in the next 12 years. This would help doctors decide if a biopsy is necessary.
Do I have to take any new medication for this study?
No, this study does not involve taking any new medications. It's about evaluating a new predictive test using existing medical information.
Can I leave the study if I change my mind?
Yes, you can choose to leave the study at any time without it affecting the care you receive from your doctors.
How to find out more
Pascal Principal investigator, MD PhD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.